iShares Biotechnology ETF
860 hedge funds and large institutions have $5.31B invested in iShares Biotechnology ETF in 2023 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 190 increasing their positions, 337 reducing their positions, and 95 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less call options, than puts
Call options by funds: $ | Put options by funds: $
18% less first-time investments, than exits
New positions opened: 78 | Existing positions closed: 95
36% less funds holding in top 10
Funds holding in top 10: 22 → 14 (-8)
44% less repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 337
Holders
860
Holding in Top 10
14
Calls
$300M
Puts
$354M
Top Buyers
| 1 | +$197M | |
| 2 | +$156M | |
| 3 | +$139M | |
| 4 |
Citigroup
New York
|
+$39.6M |
| 5 |
Two Sigma Advisers
New York
|
+$20.5M |
Top Sellers
| 1 | -$152M | |
| 2 | -$98.3M | |
| 3 | -$72.5M | |
| 4 |
E
Ergoteles
New York
|
-$59.5M |
| 5 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
-$52.6M |